CurrentMass General Brigham Health PlanPolicy 111

Medical Necessity Guidelines Papzimeos (zopapogene imadenovec-drba)

Medical necessity guidelines for use of Papzimeos in adults with recurrent respiratory papillomatosis (RRP), including prior authorization requirements across plan types and basic dosing/administration expectations.

Policy Summary

PayerMass General Brigham Health Plan

PolicyMedical Necessity Guidelines Papzimeos (zopapogene imadenovec-drba)

Policy CodePolicy 111

Change TypeNo material change

Effective DateMay 1, 2026

Next Review Date

Key ActionObtain prior authorization and document age ≥18, biopsy-confirmed RRP, evidence of surgical debulking, and specialty prescriber or consult.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

Adults (≥18)Age requirement

J3404Authorized billing code

5x10^11 x4Dose schedule

Commercial/MA/ACO/SCOPrior auth applies to

FDA 2025Regulatory status

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Initial therapy / Medical necessity criteria

Covered when ALL of the following are met

Eligibility and clinical prerequisites: 1) Member is at least 18 years of age; 2) Diagnosis of recurrent respiratory papillomatosis (RRP) confirmed by biopsy; 3) Member either has undergone or will undergo surgical debulking prior to administration of Papzimeos; 4) Medication is prescribed by, or in consultation with, a pulmonologist, oncologist, thoracic surgeon, or otolaryngologist.
Dosing and administration: Papzimeos is for subcutaneous injection only. Recommended dose: 5 x 10^11 particle units per injection administered four times over a 12-week period. Perform surgical debulking of visible papilloma prior to the initial administration, and prior to the 3rd and 4th administrations if papilloma remain visible.

This policy does not list any explicit clinical exclusions. The billing code shown is provided for informational purposes only and its inclusion does not by itself constitute or imply coverage or reimbursement.

No specific "not medically necessary" conditions are enumerated in this document; however, available evidence notes that longer-term durability data are still needed to define the sustained clinical benefit of Papzimeos. Real-world integration and use will depend on evolving postmarketing evidence, payer coverage decisions, and the operational feasibility of administering the therapy within otolaryngology and related practice settings.

Coding and Dosing

Authorized HCPCS CodeHCPCSCovered

J3404

Injection, zopapogene imadenovec-drba suspension, per therapeutic dose

Dose schedule — Papzimeos

Dose per injection5 x 10^11 particle units per injection

Number of injectionsFour injections

Treatment interval/durationAdministered over a 12‑week period

Route of administrationSubcutaneous injection only

Debulking guidanceSurgical debulking of visible papilloma prior to initial dose and prior to 3rd and 4th doses if still visible

Provider Actions, Prior Authorization, and Documentation

Prior Authorization

Prior Authorization Required

Prior authorization is required for Papzimeos across applicable plan types. Failure to obtain prior authorization may result in denial of coverage.

Medicare Advantage: Prior authorization required. Mass General Brigham Health Plan follows CMS NCDs, LCDs, LCAs, and Medicare manuals; when absent, plan medical policies apply.
Mass General Brigham ACO: Prior authorization required. Criteria reference the MassHealth Drug List (Table 5: Immunological Agents).
One Care and SCO: Prior authorization required. Follows CMS guidance; if Medicare criteria are not met, MassHealth criteria apply.
Commercial and QHP: Prior authorization required. Managed by Prime Therapeutics — see Prime Therapeutics policy for Papzimeos.

Step Therapy

No step therapy requirements are specified for Papzimeos in the source policy.

Documentation Required

Required Clinical Documentation

Document the clinical justification for Papzimeos prior authorization requests. Include patient age, biopsy confirmation of RRP, evidence of debulking (performed or planned) prior to administration, and specialty provider involvement or consultation.

Age: patient is ≥ 18 years
Diagnosis: RRP confirmed by biopsy
Debulking: evidence that the patient has or will undergo debulking prior to administration
Prescriber: prescribed by or in consultation with a pulmonologist, oncologist, thoracic surgeon, or otolaryngologist

Denial Risk

Denial Risk if Prior Authorization Not Obtained

Prior authorization must be obtained for applicable plans before claim submission. Lack of prior authorization may lead to claim denial or retrospective denial of coverage.

Applicable plans include: Medicare Advantage, Mass General Brigham ACO, One Care and SCO, Commercial and Qualified Health Plans
For Commercial and QHP members, authorization is coordinated via Prime Therapeutics

Background

Recurrent respiratory papillomatosis (RRP) is a chronic, benign but often debilitating airway disease caused primarily by human papillomavirus (HPV) types 6 and 11, characterized by repeated growth of papillomas throughout the airway and frequent need for surgical debridement to maintain airway patency and voice. Surgical approaches have been the mainstay of care because no curative treatment previously existed; adjuvant agents such as bevacizumab have been used in refractory cases. In 2025 the FDA approved Papzimeos (zopapogene imadenovec-drba), the first gene therapy for adult RRP, which uses a non-replicating adenoviral vector to stimulate a targeted immune response against HPV-6 and HPV-11 infected tissue and aims to reduce cumulative surgical burden, though longer-term durability is still under evaluation.

Definitions and Indication

Papzimeos — description & mechanism

ProductPapzimeos (zopapogene imadenovec-drba)

MechanismNon-replicating adenoviral vector-based immunotherapy designed to generate an immune response directed against HPV‑6 and HPV‑11 infected cells

FDA‑approved indicationTreatment of recurrent respiratory papillomatosis (RRP) in adults

FDA‑Approved Indication — Papzimeos

IndicationTreatment of recurrent respiratory papillomatosis (RRP) in adults

PopulationAdults (≥18 years)

Regulatory statusFDA‑approved (2025) — per policy summary of evidence